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The spinal muscular atrophies (SMAs) are a genetically and clinically heterogeneous group of disorders characterized by degeneration
and loss of anterior horn cells in the spinal cord, leading to muscle weakness and atrophy. Spinal muscular atrophy with pontocerebellar
hypoplasia (SMA-PCH, also known as pontocerebellar hypoplasia type 1 [PCH1]) is one of the rare infantile SMA variants that include
additional clinical manifestations, and its genetic basis is unknown.We used a homozygosity mapping and positional cloning approach
in a consanguineous family of Ashkenazi Jewish origin and identiﬁed a nonsense mutation in the vaccinia-related kinase 1 gene (VRK1)
as a cause of SMA-PCH.VRK1, one of threemembers of themammalian VRK family, is a serine/threonine kinase that phosphorylates p53
and CREB and is essential for nuclear envelope formation. Its identiﬁcation as a gene involved in SMA-PCH implies new roles for the VRK
proteins in neuronal development and maintenance and suggests the VRK genes as candidates for related phenotypes.The spinal muscular atrophies (SMAs) are a genetically
and clinically heterogeneous group of disorders character-
ized by degeneration and loss of anterior horn cells in
the spinal cord, leading to muscle weakness and atrophy.1
Proximal SMA (types I–IV [MIM 253300, 253550, 253400,
271150]) accounts for 80%–90% of all SMA cases and
is primarily caused by recessive mutations in SMN1
(MIM 600354), with homozygous absence of exon 7 in >
95% of cases.2 Non-SMN1 SMAs include nonproximal
SMA (MIM 181405, 182960, 271220, 600794, 605726,
607088, 611067), bulbar palsy (MIM 211500, 211530,
601104), spinobulbar muscular atrophy (SBMA [MIM
313200]), and infantile SMA variants also known as
‘‘SMA plus.’’1 These variants are characterized by SMA
with additional or atypical features. They include SMA
with respiratory distress (SMARD [MIM 604320]), which
can be caused by recessive mutations in IGHMBP2 (MIM
600502); infantile lethal X-linked SMAwith arthrogryposis
and congenital fractures (SMAX2 [MIM 301830]), caused
by mutations in UBE1 (MIM 314370); SMA1 with arthrog-
ryposis and bone fractures (MIM 271225), which is yet to
be mapped; and SMA with pontocerebellar hypoplasia
(SMA-PCH [MIM 607596]), also known as PCH type 1.
SMA-PCH is also associated with polyhydramnios, congen-
ital contractures (secondary to reduced fetal movement),
and respiratory insufﬁciency, leading to early death (mostly
before 1 yr) in the original cases described.3 However, in
recent years, a broader clinical spectrum has emerged,
with later onset of hypotonia, varying degrees of cerebellar
or pontine hypoplasia and atrophy, peripheral nerve
involvement, and longer survival.4
SMA-PCH is regarded as a subtype of both SMA and PCH
and is also known as PCH1 (MIM 607596). All PCH
syndromes include a small cerebellum and brainstem,The Amerand progressive microcephaly is common. The six cur-
rently described PCH subtypes are distinguished by addi-
tional features (OMIM; see Web Resources). SMA is found
only in PCH1. PCH2, which is genetically heterogeneous
(MIM 277470, 612389, 612390), is characterized by pro-
gressive cerebral atrophy, extrapyramidal dyskinesia and
chorea, seizures, lack of motor and mental development,
and normal spinal cord ﬁndings. PCH3 (MIM 608027),
mapped to choromosome 7 in a single family, is character-
ized by optic atrophy, seizures, truncal hypotonia, speciﬁc
facial features, and lack of extrapyramidal symptoms.
PCH4 (MIM 225753) is a severe form with infantile
encephalopathy, olivopontine atrophy, and early lethality.
In PCH5 (MIM 610204), described in a single family, there
is fetal onset of a seizure-like activity and severe olivopon-
tocerebellar hypoplasia. PCH6 is a single-family, fatal,
infantile form with mitochondrial respiratory chain
defects and lack of motor or mental development. Interest-
ingly, all genes so far identiﬁed as mutated in PCH are
involved in tRNA processing: PCH2A and PCH4 are caused
by TSEN54 (MIM 608755) mutations,5 PCH2B (MIM
612389) is caused by TSEN2 (MIM 608753) mutations,5
and PCH2C (MIM 612390) is caused by TSEN34 (MIM
608754) mutations.5 These genes encode noncatalytic
(TSEN54) and catalytic (TSEN2 and TSEN34) subunits of
the tRNA splicing endonuclease. PCH6 is caused by muta-
tions in mitochondrial arginyl-tRNA synthetase (RARS2
[MIM 611524]).6
The genetic basis of SMA-PCH has not been determined.
The SMN1 locus has been excluded in SMA-PCH, and tRNA
defects identiﬁed inother formsof PCHduring the courseof
our study were excluded on the basis of genomic location.
We report a consanguineous family of Ashkenazi Jewish
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The proband (IV-12) was the youngest daughter of ﬁrst-
cousin parents. Pregnancy was remarkable only for micro-
cephaly noted on ultrasound at 7 mo gestation. At birth,
weight was 2750 g, head circumference (HC) was 28.5cm
(6 SD), and poor sucking was noted. Brain CT was unre-
markable except for microcephaly, and there was no
evidence of craniosynostosis on skull X-rays. TORCH
serology was negative. HC at 19 mo of age was 38 cm
(7.9 SD). Developmental delay became evident during
the ﬁrst two years (sitting at age 1 yr, assisted walking at
2 yrs), and the proband developed upper limb ataxia, brisk
deep tendon reﬂexes (DTRs), and bilateral equinovarus.
Results of electromyography (EMG), nerve conduction
velocity (NCV), and somatosensory evoked potential
(SEP) studies performed at age 2 yrs were consistent with
motor and sensory neuropathy due to chronic denerva-
tion, more evident peripherally. Speciﬁcally, NCVs were
normal, SEP showed diminished sensory nerve action
potential (SNAP) in the right sural nerve, and EMG
revealed fasciculations and ﬁbrillations, consistent with
motor neuron disease. At age 3 yrs, brain MRI showed
a small cerebellar vermis and a large cisterna magna,
compatible with cerebellar hypoplasia, and spine MRI
was normal. (The MRI was performed in 1994 at a private
facility, and images are unfortunately unavailable). Con-
currently, a sural nerve biopsy was normal and muscle
biopsy showed neurogenic atrophy typical of SMA (Fig-
ure 2). Cognitive ability was assessed as mild mental
retardation. After corrective surgery, the proband began
walking independently at age 3 yrs, though with ataxia.
Additional studies at age 8 yrs included electron
Figure 2. Muscle Biopsy of the Proband
at Age 3 Yrs
Frozen hematoxylin-eosin-stained section
shows bundles of larger-diameter ﬁbers
adjacent to bundles of very small ﬁbers. In-
termingled with the large ﬁbers are a few
angular ﬁbers, singly and in small groups.
There is no abundance of central nuclei,
necrosis, regeneration, or other ﬁber struc-
tural changes. Collagen encircling atro-
phic ﬁbers is observed.
microscopy of a skin biopsy and
isoelectric focusing of serum trans-
ferrin, which were both normal.
Creatine phosphokinase (CPK) was
not elevated (40 IU/l), and urinary
organic acids were normal. Disease
progression led to severe weakness,
and the child became wheelchair-
bound and incontinent, with sleep
disturbance, increasing swallowing
difﬁculties, severe ataxia, and progressive intercostal
muscle weakness. A percutaneous gastrostomy was per-
formed to allow feeding, but a few days after this proce-
dure, the proband died at age 11.5 yrs. Testing for deletion
of exon 7 in SMN1 was negative.
The proband had a previously deceased older sister (IV-6)
who was treated at another institution for the same condi-
tion. Review of her clinical records showed that after
a normal pregnancy, birthweight was 3100 g and micro-
cephaly was noted (HC 30.5 cm [3 SD]). Investigations
for microcephaly included skull X-rays, optic fundi exam-
ination, and TORCH serology, all of which were normal.
She gained weight slowly but was otherwise healthy. De-
layedmotormilestones were apparent in the ﬁrst year (roll-
ing over at 8mo, sitting at 15mo, standing at 18mo). Early
language and social skills developed appropriately. Investi-
gations at 6 mo included repeated skull X-rays demon-
strating closure of skull sutures. EEG showed abnormal gen-
eralized discharges. Auditory brainstem response (ABR),
visual evoked potential (VEP), and electroretinography
(ERG) were normal. Brain CT scan showed mild bilateral
enlargement of the posterior horns of the lateral ventricles,
a large cisterna magna, and minimal cortical atrophy.
Neurological examination at 2 yrs showed tongue fascicula-
tions, hypotonia with brisk DTRs, and ataxia. Concur-
rently, she was noted to have bilateral equinovarus defor-
mities, which necessitated splinting. At age 3 yrs, she was
enrolled in a special education program. General func-
tioning was severely impaired by ataxia, but language
comprehension and social skills were relatively spared. At
age 5 yrs, she could crawl on her knees independentlyFigure 1. Linkage and Homozygosity Mapping of Markers on 14q32 to SMA-PCH in a Consanguineous Family
Affected individuals are shown in black. STR genotypes in the critical region are shown below each sampled individual, where numbers
indicate amplicon size (bp). The disease-associated haplotype is shaded in yellow or yellow-orange. Only IV-12 is homozygous by
descent for the region boxed in red.The American Journal of Human Genetics 85, 281–289, August 14, 2009 283
and walk with the aid of a walker and braces. Examination
revealed progressive microcephaly (HC 42.5cm [6 SD]),
distal muscle atrophy, brisk DTRs, no nystagmus, and
obvious hand tremor and ataxia. EMG and NCV at this
time showed demyelinating peripheral neuropathy. CSF
protein (age 6 yrs) was 24 mg%. Brain CT scan at age 7
yrs showed cerebellar hypoplasia with suspected pontine
hypoplasia (Figure 3). A CT of the cervical spine was
normal. Additional laboratory tests showed normal female
karyotype (46,XX), negative urinary oligosaccharides, and
normal activity levels of the following lysosomal enzymes:
Hexosaminidase A (Tay-Sachs disease [MIM 272800]), Gal-
actocerebrosidase (Krabbe disease [MIM 245200]), Arylsul-
fatase A (metachromatic leukodystrophy [MIM 250100]),
and beta-Galactosidase 1 (GM1 gangliosidosis [MIM
230500]). At age 8 yrs, incontinence developed, muscle
strength decreased, and she became nonambulatory. Sleep
disturbances appeared and progressed, with frequent awak-
enings. At age 9 yrs, a percutaneous gastrostomy was in-
serted because of increasing feeding and swallowing difﬁ-
culties. A muscle biopsy performed at that time revealed
neurogenic atrophy typical of SMA. Her disease progressed
and she died at age 9.5 yrs. The family refused autopsy for
both daughters. To summarize, both sisters presented with
motor neuron disease consistent with SMA: clinically pro-
minent progressive muscular weakness, EMG reﬂecting
chronic denervation (fasciculations and ﬁbrillations), and
typical muscle pathology (neurogenic atrophy; see Fig-
ure 2). Both had progressive microcephaly of prenatal
onset, mental deﬁciency, and signiﬁcant ataxia, correlated
with cerebellar hypoplasia on brain imaging (Figure 3).
There were equivocal features of sensory neuropathy and
Figure 3. Brain CT Scan of the Proband’s
Sister at Age 7 Yrs, in 1989
(A) Cerebellar vermis hypoplasia, commu-
nicating fourth ventricle and cisterna ma-
gna (arrow).
(B) Cerebellar vermis hypoplasia (arrow).
(C) Large cisterna magna and cerebellar
hemisphere hypoplasia.
evidence for upper motor neuron
involvement. The disease was progres-
sive from infancy but protracted, with
death at 9.5 and 11.5 years. Notably,
both girls had normal birth weights
and did not have congenital arthrog-
ryposis. The disease process was sym-
metric; there were no seizures, dykine-
sia, or chorea and no evidence of
severe respiratory distress or diaphrag-
matic dysfunction. Both sisters were
independently diagnosed with SMA-
PCH, by two different clinical teams.
Their cousin (IV-14), also the product
of a consanguineous marriage within
the extended family, was reported by
his parents to have had a similar phenotype. He died at
age 8 yrs, and his medical records are unavailable.
After approval by an institutional review board and the
National Helsinki Committee for Genetic Studies, homo-
zygosity mapping was performed on the proband (IV-12),
who was the single affected individual for whom DNA
was available, and on all other available relatives
(Figure 1). DNA isolated from blood was typed with the
use of the Affymetrix GeneChip 250K Nsp SNP array.
SNP data were examined for informative genomic regions
that were longer than 5 Mb and homozygous in the
proband but not in any of her healthy siblings. Bound-
aries of homozygous segments in the proband were
deﬁned by the presence of two heterozygous SNPs in
any moving 10-SNP window. A single 6.24 Mb region
on chromosome 14 (including 576 SNPs from rs7146008
at 90,663,054 to rs17095290 at 96,905,397) was identiﬁed
as homozygous by descent only in the affected proband.
In addition, linkage analysis on genome-wide SNP data
was performed with the use of Superlink Online,7,8 as-
suming autosomal-recessive inheritance of SMA-PCH,
high penetrance (99%), rare frequency of the disease allele
in the general population (0.001), and no phenocopies. A
multipoint LOD score of 3.3 was obtained for a 200 kb
interval within the 6.24 Mb chromosome 14 homozygous
region. No other region fulﬁlled homozygosity criteria or
had signiﬁcant LOD scores. Fine mapping of the homozy-
gous region with the use of short tandem repeat (STR)
markers deﬁned a minimal 6.04 Mb interval between
D14S995 (cen) and D14S65 (tel) (Figure 1), a region con-
taining 71 known and predicted genes (UCSC Genome
Browser).284 The American Journal of Human Genetics 85, 281–289, August 14, 2009
An obvious candidate gene in this region was Ataxin-3
(ATXN3), because expansion of a coding CAG repeat in
ATXN3 causes spinocerebellar ataxia type 3 (SCA3 or
Machado-Joseph disease [MJD, MIM 109150]).9 MJD is an
autosomal-dominant, adult-onset disease, whereas SMA-
PCH is an autosomal-recessive disease of prenatal or infan-
tile onset, but the cerebellum and spinocerebellar tracts are
major targets of both diseases, so conceivably, a recessive
ATXN3 mutation could lead to SMA-PCH. We examined
this possibility as follows (data not shown): (1) All ATXN3
exons (including 50 and 30 UTRs) were sequenced in
both parents and the affected proband in both directions.
No previously unreported variants were identiﬁed. (2)
ATXN3 CAG repeats were genotyped in the entire family
(ATXN3-CAG, Figure 1), and no expansion was identiﬁed.
(3) For the purpose of ruling out a nonexonic mutation
affecting ATXN3 regulation, allele-speciﬁc ATXN3 expres-
sion was analyzed in cDNA from lymphoblastoid cell lines
of both parents. Both parents (obligate carriers) were
heterozygous for a known SNP (rs12895357) in exon 10
and for the ATXN3 CAG repeat. Semiquantitative RT-PCR
revealed comparable biallelic expression of ATXN3 in
both assays in each parent. (4) ATXN3 splicing patterns
were tested in both parents and in unrelated control indi-
viduals. No differences were observed in six different
RT-PCR amplicons spanning the entire ATXN3 transcript.
Other genes in theminimal homozygous regionwere prior-
itized on the basis of cerebellar and spinal cord expression
via the use of publicly available data on tissue-speciﬁc
expression (Genecards) and RT-PCR on human cerebellar
RNA (Ambion, TX, USA). In addition, we assessed known
human phenotypes and murine models of genes in the
candidate region. The proband’s DNA was fully sequenced
for 27 genes in the region, and no mutations were found
(Table 1).
In the VRK1 (vaccinia related kinase) gene (MIM
602168), the proband was found to have a homozygous
C>T transition in nt 4 of VRK1 exon 12 (NM_003384,
1072 C>T; chr14:96,412,123 on hg18, NCBI Build 36.1,
displayed on the UCSC Genome Browser), creating a stop
codon (R358X) (Figure 4A) within a highly conserved
KKRKK nuclear localization signal (NLS) (Figures 4B and
4C). Semiquantitative comparison of the expression pat-
terns of mutant and wild-type alleles in the heterozygous
parents suggests that the mutant sequence is associated
with signiﬁcantly lower mRNA levels than the wild-type,
perhaps as a result of nonsense-mediated decay (Figure 4D).
Familial segregation of the mutation was as expected,
revealing that the proband’s aunt (III-3) and uncle (III-4)
are indeed both carriers of VRK1 R358X.
VRK1 exon 12 was sequenced in 449 normal Ashkenazi
Jewish controls, and two VRK1 R358X carriers were identi-
ﬁed. The allele frequency is therefore 1/449 (95% CI:
1/625–1/263), conﬁrming the rarity of the SMA-PCH
mutation.
VRK1 was originally identiﬁed as a novel serine-threo-
nine kinase in a screen for genes enriched in fetal versusThe Ameradult liver and involved in cell cycle regulation.10 The
VRK1 gene (NM_003384) comprises 13 exons encoding
a 1720 nt transcript, including a 106 bp 50 UTR and
a 423 bp 30 UTR. VRK1 encodes a 396 aa protein
(NP_003375), with an N-terminal serine/threonine kinase
domain (aa 173–185), a C-terminal NLS (residues 356–
360), an endosomal and lysosomal targeting sequence
(aa 304–320), and a basic-acidic-basic (BAB) motif at the
C terminus (Figure 4B). Through homology searches, the
mammalian VRK family was found to include two
additional members: VRK2, which associates with the
Table 1. The SMA-PCH Chromosome 14 Homozygous




Symbol MIM No. Gene Name
1 ASB2 605759 Ankyrin repeat and SOCS box-containing 2
2 ATXN3 607047 Ataxin 3
3 BDKRB1 600337 Bradykinin receptor B1
4 BDKRB2 113503 Bradykinin receptor B2
5 CHGA 118910 Chromogranin A
6 CPSF2 606028 Cleavage and polyadenylation speciﬁc
factor 2
7 DDX24 606181 DEAD (Asp-Glu-Ala-Asp) box polypeptide 24
8 DICER1 606241 Dicer 1
9 FBLN5 604580 Fibulin 5
10 GPR68 601404 G protein-coupled receptor 68
11 GSC 138890 Goosecoid homeobox
12 IFI27L2 611319 Interferon, alpha-inducible protein 27-like 2
13 ITPK1 601838 Inositol 1,3,4-triphosphate 5/6 kinase
14 MOAP1 609485 Modulator of apoptosis 1
15 NDUFB1 603837 NADH dehydrogenase (ubiquinone) 1 beta
16 NESPRIN3 610861 Nesprin 3
17 OTUB2 608338 OTU domain, ubiquitin aldehyde binding 2
18 PAPOLA 605553 Poly(A) polymerase alpha
19 PRIMA1 - Proline-rich membrane anchor 1
20 SERPINA3 107280 Serine proteinase inhibitor, clade A,
member 3
21 SERPINA4 147935 Serine proteinase inhibitor, clade A,
member 4
22 SERPINA5 601841 Serine proteinase inhibitor, clade A,
member 5
23 SERPINA6 122500 Serine proteinase inhibitor, clade A,
member 6
24 SERPINA9 - Serine proteinase inhibitor, clade A,
member 9.
25 SLC24A4 609840 Solute carrier family 24, member 4, isoform 3
26 TCL1A 186960 T cell leukemia/lymphoma 1A (TCL1A),
transcript variant 2
27 TRIP11 604505 thyroid hormone receptor interactor 11ican Journal of Human Genetics 85, 281–289, August 14, 2009 285
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endoplasmic reticulum (ER) and the nuclear envelope (NE)
and is enzymatically active, and VRK3, which is nuclear
and enzymatically inactive as a result of key amino acid
substitutions.10,11 C. elegans and Drosophila have a single
VRK ortholog, CeVRK1 and NHK1, respectively.
VRK1 is ubiquitously expressed, including in fetal and
adult brain and cerebellum (10 and data not shown). At
the subcellular level, it is mainly a nuclear protein, with
a small fraction found in the cytoplasm and membrane
compartments11,12 (Human Protein Atlas). Dynamics of
subcellular localization have not been studied in mam-
mals, but in Drosophila and C. elegans, localization is cell-
cycle-dependent: NHK-1 is cytoplasmic in the S phase,
binds condensing chromatin in prophase, and is excluded
from chromatin at the end of mitosis.13 CeVRK-1 relocates
to the nuclear rim just before mitosis and binds to chro-
matin from nuclear envelope breakdown until the end of
mitosis.14
VRK1 function has been most extensively studied in the
context of cellular proliferation and tumorigenesis
(reviewed in 15). VRK1 stabilizes p53 by phosphorylating
its transactivation domain, thereby preventing its interac-
tion with Mdm2. Normally, increased p53 proteolytically
downregulates VRK1, but this autoregulatory loop is dis-
rupted in a number of tumors, where increased VRK1 levels
correlate with proliferation markers.16 VRK1 also phos-
phorylates other transcription factors, including c-JUN,
ATF-2, and CREB, and has recently been shown to be an
early-response gene required for G1/S cell cycle progres-
sion,17,18 at least in part through CREB-mediated regula-
tion of cyclin D1 expression.18 Identiﬁcation of Myc as
an activator of VRK1 expression is further evidence of its
signiﬁcance for cellular proliferation.18 In addition to these
functions, VRK1 plays an important role in nuclear enve-
lope and chromatin organization. VRK1 phosphorylates
histone H3 during mitosis, and VRK inactivation in C. ele-
gans and Drosophila results in chromatin hypercondensa-
tion.19 In the nuclear envelope, VRK1 is essential for
formation of nuclear membrane pore complexes, at least
in part through its interaction with BAF (barrier to autoin-
tegration factor).14 VRK1 phophorylates BAF during
mitosis, thus releasing it from chromatin, to which it is
bound during interphase.14,20 BAF release is accompanied
by release of nuclear lamina proteins, including emerin,
a release critical for NE assembly. Lack of the single VRK
gene in Drosophila is lethal.21The AmerOur results suggest that in humans, VRK1 deﬁciency
causes a neurological phenotype that is both develop-
mental and degenerative. Known VRK1 functions suggest
interesting possibilities for its role in nervous system devel-
opment and neuronal maintenance. Although VRK1 has
not been studied in this context, in mice, VRK1 is ex-
pressed in the brain and spinal cord in all stages of develop-
ment, including the adult (Allen Brain Atlas and data not
shown). The VRK1/p53 autoregulatory loop may be rele-
vant not only for malignancy but also for development
and maintenance of the nervous system. p53 regulates
cell division and death during nervous system develop-
ment and in response to neuronal insult or injury during
life (reviewed in 22). Recessive mutations in ATM, which
phosphorylates p53 in response to DNA damage, cause
ataxia telangiectasia (MIM 208900), in which loss of cere-
bellar neurons and ataxia are prominent features. p53
interacts directly with SMN1, an association disrupted by
SMN1mutations associated with SMA,23 although the rele-
vance of this interaction to SMA pathogenesis is unclear.24
Its role in the nuclear envelope may link VRK1 defects to
the laminopathies, which have neuromuscular manifesta-
tions (reviewed in 25). With respect to the essential role of
VRK1 in BAF function, Baf null ﬂies have small brains,
missing imaginal discs, and defects in cell proliferation
and differentiation in the thoracic ganglia and the brain
hemispheres.26 The role of VRK1 in CREB activation
suggests that VRK1 mutations may lead to impaired
CREB signaling, which can result in both developmental
and degenerative neurological disease. Cofﬁn Lowry
syndrome (MIM 303600) is caused by mutations in RSK2,
another CREB kinase. Rubinstein Taybi syndrome (MIM
180849) can be caused by mutations in CREBBP, a CREB-
binding protein. CREB depletion in the postnatal mouse
brain leads to progressive neurodegeneration,27 and inter-
ference with CREB-dependent transcription is a feature of
polyglutamine stretches, common in spinocerebellar
ataxias.28 CREB also binds to the SMN promoter and
increases SMN expression, so its deﬁciency could promote
an SMA phenotype.29
As in any identiﬁcation of a gene for a rare recessive
disease in a single family, we cannot exclude the possibility
of a deleterious mutation in one of the genes in the region
that were not sequenced in the proband. However, the
presence of a homozygous null mutation suggests that
VRK1 is very highly likely to be an SMA-PCH gene.Figure 4. Homozygous VRK1 Nonsense Mutation in SMA-PCH
(A) Genomic sequence of the VRK1 exon 12 region in informative family members. The proband is homozygous for a C>T transition
that creates a TGA termination codon.
(B) Schematic representation of the VRK1 protein, including the ATP binding site, kinase domain, and nuclear leader sequence (NLS).
Amino acid sequence of the NLS is indicated below, with the R358X mutation shown in red.
(C) Species conservation of amino acids in the R358X region.
(D) Allele-speciﬁc expression of VRK1 in R358X carriers. VRK1 exons 8 (ex8) and 12 (ex12) were sequenced in both genomic DNA and
cDNA of a carrier of the R358Xmutation. cDNAwas extracted from an Epstein-Barr virus (EBV)-transformed B cell line. Exon 8 contains
a known polymorphism (rs2230532) that also segregates in this family, and the exon 12 R358Xmutation corresponds to 1072C>T in the
cDNA (NM_003384). Top: genomic DNA sequences, showing equal biallelic content in both exon 8 and exon 12 sequences. Bottom:
Unequal allelic expression in cDNA, where the wild-type allele predominates over the mutant (>70%).ican Journal of Human Genetics 85, 281–289, August 14, 2009 287
Veriﬁcation would require identiﬁcation of additional
patients with VRK1 mutations and additional studies
addressing the mechanisms by which VRK1 mutation
leads to neuronal disease. Previous genes implicated in
PCH without SMA are all involved in tRNA processing,5,6
suggesting that VRK1 may be speciﬁcally important for
spinal motor neuron survival or that it may also play
a role in tRNA processing. In either case, identiﬁcation of
a VRK1 mutation as a cause of SMA-PCH points to new
roles for this protein and suggests VRK2 (chromosome
2p16) and VRK3 (chromosome 19q13) as candidate genes
for related phenotypes, including other pontocerebellar
hypoplasias and other spinal muscular atrophies.
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